Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).

ABSTRACT:

Aim

To determine the safety of a higher starting dose of basal insulin in overweight/obese patients with type 2 diabetes (T2D).

Materials and methods

This 16-week, randomized, multicentre, open-label trial enrolled adults with T2D (body mass index 25-40 kg/m² ) and suboptimal glycaemic control (glycated haemoglobin [HbA1c] 7.5-11.0% [58-97 mmol/mol] and fasting plasma glucose [FPG] >9.0 mmol/L) with two to three oral anti-hyperglycaemic drugs at 51 centres in China. Patients were randomized (1:1) to a higher (0.3 U/kg) or standard (0.2 U/kg) starting dose of insulin glargine 100 U/mL, which was then titrated to achieve a self-monitored fasting blood glucose (FBG) of 4.4 to 5.6 mmol/L. The primary endpoint was the percentage of patients with ≥1 episode of overall c

SUBMITTER: Ji L 

PROVIDER: S-EPMC7187195 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature